Table 2.

Multivariate regression models for association between non-permissive DPB1 TCE3 mismatches and clinical outcome.

	Permissive HLA-DPB1 mismatch (N = 585)	HLA-DPB1 match (N = 239)		Non-Permissive HLA-DPB1 mismatch (N = 457)		Non-Permissive HLA-DPB1 GvH (N=226)		Non-Permissive HLA-DPB1 HvG (N=231)
	Ref.	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value
Overall mortalitya	1	0.94 (0.78–1.14)	0.56	1.16 (0.99–1.35)	0.05	1.11 (0.92–1.35)	0.27	1.20 (1.00–1.44)	0.05
Treatment-related mortalityb	1	0.86 (0.68–1.11)	0.03	1.3 (1.06–1.53)	0.009	1.29 (1.03–1.60)	0.03	1.27 (1.01–1.58)	0.04
Relapsec	1	1.31 (0.99–1.73)	0.05	0.80 (0.62–1.05)	0.1	0.55 (0.37–0.80)	0.002	1.09 (0.8–1.48)	0.6
aGVHD C–Dd	1	0.96 (0.73–1.26)	0.77	1.27 (1.02–1.57)	0.03	1.34 (1.03–1.74)	0.03	1.20 (0.92–1.56)	0.17

^aadjusted for disease, disease status, GVHD prophylaxis, use of in vivo T cell depletion, preparative regimen, and recipient age at transplant.

^badjusted for disease status, GVHD prophylaxis, use of in vivo T cell depletion, preparative regimen and recipient age at transplant.

^cadjusted for disease and disease status.

^dadjusted for disease, disease status, graft type and year of transplant.